A Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-TMPRSS6-Lrx Administered Subcutaneously to Healthy Volunteers
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Sapablursen (Primary)
- Indications Thalassaemia
- Focus Adverse reactions
- Sponsors Ionis Pharmaceuticals
- 17 Jan 2019 Status changed from active, no longer recruiting to completed.
- 04 Dec 2018 Results assessing safety of IONIS-TMPRSS6-LRx in healthy volunteers, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 31 Jul 2018 Status changed from recruiting to active, no longer recruiting.